Drivers of and Barriers to Adherence to Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Treatment Management Plans: A Multi-National Qualitative Study

References

• Holekamp NM. Review of neovascular age-related macular degeneration treatment options. Am J Manag Care. 2019;25(10 Suppl):S172–s181.
   PubMedGoogle Scholar
• Wolf A, Langmann T. Anti-VEGF-A/ANG2 combotherapy limits pathological angiogenesis in the eye: a replication study. EMBO Mol Med. 2019;11(5). doi:10.15252/emmm.201910362
   PubMed Web of Science ®Google Scholar
• Gale RP, Mahmood S, Devonport H, et al. Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye. 2019;33(Suppl 1):1–21. doi:10.1038/s41433-018-0300-3
   PubMed Web of Science ®Google Scholar
• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Heal. 2014;2(2):e106–116. doi:10.1016/S2214-109X(13)70145-1
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9):2653–2664. doi:10.2337/diacare.26.9.2653
   PubMed Web of Science ®Google Scholar
• MacKinnon JR, Forrester JV. Diabetic retinopathy. In: Was JAH, Shalet SM, editors. Oxford Textbook of Endocrinology and Diabetes. Oxford, U.K.: Oxford University Press; 2002:1764–1778.
   Google Scholar
• Subhi Y, Sørensen TL. Neovascular age-related macular degeneration in the very old (≥90 years): epidemiology, adherence to treatment, and comparison of efficacy. J Ophthalmol. 2017;2017:7194927. doi:10.1155/2017/7194927
   PubMed Web of Science ®Google Scholar
• Miskala PH, Bass EB, Bressler NM, et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST report no. 12. Ophthalmology. 2004;111(11):1981–1992.
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Sharma S, Shah G. Utility values and diabetic retinopathy. Am J Ophthalmol. 1999;128(3):324–330. doi:10.1016/S0002-9394(99)00146-4
   PubMed Web of Science ®Google Scholar
• Dervenis N, Mikropoulou AM, Tranos P, Dervenis P. Ranibizumab in the treatment of diabetic macular edema: a review of the current status, unmet needs, and emerging challenges. Adv Ther. 2017;34(6):1270–1282. doi:10.1007/s12325-017-0548-1
   PubMed Web of Science ®Google Scholar
• Droege KM, Caramoy A, Kersten A, et al. Patient preference of ranibizumab treatment regimen for neovascular age-related macular degeneration - monthly injections versus pro re nata. Graefes Arch Clin Exp Ophthalmol. 2014;252(1):31–34. doi:10.1007/s00417-013-2412-6
   PubMed Web of Science ®Google Scholar
• Jelin E, Wisløff T, Moe MC, Heiberg T. Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration. Acta Ophthalmol. 2018;96(8):804–811. doi:10.1111/aos.13847
   PubMed Web of Science ®Google Scholar
• Mueller S, Agostini H, Ehlken C, Bauer-Steinhusen U, Hasanbasic Z, Wilke T. Patient preferences in the treatment of neovascular age-related macular degeneration: a discrete choice experiment. Ophthalmology. 2016;123(4):876–883. doi:10.1016/j.ophtha.2015.12.001
   PubMed Web of Science ®Google Scholar
• Droege KM, Muether PS, Hermann MM, et al. Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Arch Clin Exp Ophthalmol. 2013;251(5):1281–1284. doi:10.1007/s00417-012-2177-3
   PubMed Web of Science ®Google Scholar
• Gohil R, Crosby-Nwaobi R, Forbes A, Burton B, Hykin P, Sivaprasad S. Caregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degeneration. PLoS One. 2015;10(6):e0129361. doi:10.1371/journal.pone.0129361
   PubMed Web of Science ®Google Scholar
• Gohil R, Crosby-Nwaobi R, Forbes A, Burton BJ, Hykin P, Sivaprasad S. Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting. Patient Prefer Adherence. 2016;10:949–955. doi:10.2147/PPA.S105536
   PubMed Web of Science ®Google Scholar
• Müller S, Ehlken C, Bauer-Steinhusen U, et al. Treatment of age-related neovascular macular degeneration: the patient’s perspective. Graefes Arch Clin Exp Ophthalmol. 2017;255(11):2237–2246. doi:10.1007/s00417-017-3739-1
   PubMed Web of Science ®Google Scholar
• Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol. 2015;160(4):725–731.e721. doi:10.1016/j.ajo.2015.06.023
   PubMed Web of Science ®Google Scholar
• Weiss M, Sim DA, Herold T, et al. Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina. 2018;38(12):2293–2300. doi:10.1097/IAE.0000000000001892
   PubMed Web of Science ®Google Scholar
• Bian W, Wan J, Smith G, Li S, Tan M, Zhou F. Domains of health-related quality of life in age-related macular degeneration: a qualitative study in the Chinese cultural context. BMJ Open. 2018;8(4):e018756. doi:10.1136/bmjopen-2017-018756
   PubMed Web of Science ®Google Scholar
• Peters CM, James AI, Tran I, et al. The impact of diabetic macular edema on the daily lives of diabetic adults—a qualitative study. Invest Ophthalmol Vis Sci. 2012;53(14):5449.
   Google Scholar
• Burton AE, Shaw R, Gibson J. Experiences of patients with age-related macular degeneration receiving anti-vascular endothelial growth factor therapy: a qualitative study. Br J Vis Impair. 2013;31(3):178–188. doi:10.1177/0264619613490517
   Google Scholar
• Hartnett ME, Key IJ, Loyacano NM, Horswell RL, DeSalvo KB. Perceived barriers to diabetic eye care: qualitative study of patients and physicians. Arch Ophthalmol. 2005;123(3):387–391. doi:10.1001/archopht.123.3.387
   PubMedGoogle Scholar
• McCloud C, Lake S. Understanding the patient’s lived experience of neovascular age-related macular degeneration: a qualitative study. Eye. 2015;29(12):1561–1569. doi:10.1038/eye.2015.167
   PubMed Web of Science ®Google Scholar
• Granström T, Forsman H, Brorsson A-L, Granstam E, Leksell J. Patients’ experiences before starting anti-VEGF treatment for sight-threatening diabetic macular oedema: a qualitative interview study. Nord J Nurs Res. 2018;38(1):11–17. doi:10.1177/2057158517709409
   Google Scholar
• Hennink MM, Kaiser BN, Marconi VC. Code saturation versus meaning saturation: how many interviews are enough? Qual Health Res. 2017;27(4):591–608. doi:10.1177/1049732316665344
   PubMed Web of Science ®Google Scholar
• Kerr C, Nixon A, Wild D. Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):269–281. doi:10.1586/erp.10.30
   PubMed Web of Science ®Google Scholar
• VERBI Software. MAXQDA 2020 [computer software]. Berlin, Germany: VERBI Software; 2019. Available from: maxqda.com. Accessed February 25, 2022
   Google Scholar
• Joffe H, Yardley L. Content and thematic analysis. In: Research Methods for Clinical and Health Psychology. London: SAGE Publications, Ltd; 2004:56–68.
   Google Scholar
• Polat O, Inan S, Özcan S, et al. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration. Turk J Ophthalmol. 2017;47(4):205–210. doi:10.4274/tjo.28003
   PubMedGoogle Scholar
• Okada M, Wong TY, Mitchell P, et al. Defining nonadherence and nonpersistence to anti-vascular endothelial growth factor therapies in neovascular age-related macular degeneration. JAMA Ophthalmol. 2021;139(7):769–776. doi:10.1001/jamaophthalmol.2021.1660
   PubMed Web of Science ®Google Scholar
• Cavan D, Makaroff L, da Rocha Fernandes J, et al. The diabetic retinopathy barometer study: global perspectives on access to and experiences of diabetic retinopathy screening and treatment. Diabetes Res Clin Pract. 2017;129:16–24. doi:10.1016/j.diabres.2017.03.023
   PubMed Web of Science ®Google Scholar
• Soubrane G, Cruess A, Lotery A, et al. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol. 2007;125(9):1249–1254. doi:10.1001/archopht.125.9.1249
   PubMed Web of Science ®Google Scholar
• Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2018;23(2):127–140. doi:10.1080/13548506.2016.1274040
   PubMed Web of Science ®Google Scholar
• Gomi F, Toyoda R, Yoon AH, Imai K. Factors of anti-vascular endothelial growth factor therapy withdrawal in patients with neovascular age-related macular degeneration: implications for improving patient adherence. J Clin Med. 2021;10(14):3106. doi:10.3390/jcm10143106
   PubMed Web of Science ®Google Scholar
• Sobolewska B, Sabsabi M, Ziemssen F. Importance of treatment duration: unmasking barriers and discovering the reasons for undertreatment of anti-VEGF agents in neovascular age-related macular degeneration. Clin Ophthalmol. 2021;15:4317–4326. doi:10.2147/OPTH.S325763
   PubMed Web of Science ®Google Scholar
• Okada M, Mitchell P, Finger RP, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021;128(2):234–247. doi:10.1016/j.ophtha.2020.07.060
   PubMed Web of Science ®Google Scholar
• Krüger Falk M, Kemp H, Sørensen TL. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol. 2013;155(1):89–95.e83. doi:10.1016/j.ajo.2012.06.031
   PubMed Web of Science ®Google Scholar
• Senra H, Balaskas K, Mahmoodi N, Aslam T. Experience of anti-VEGF treatment and clinical levels of depression and anxiety in patients with wet age-related macular degeneration. Am J Ophthalmol. 2017;177:213–224. doi:10.1016/j.ajo.2017.03.005
   PubMed Web of Science ®Google Scholar